Towards a systematic characterization of the antiprotozoal activity landscape of benzimidazole derivatives

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 21, 2010, Pages 7380-7391

  Pérez Villanueva, Jaime ^a   Santos, Radleigh ^b   Hernández Campos, Alicia ^a   Giulianotti, Marc A ^b   Castillo, Rafael ^a   Medina Franco, Jose L ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Activity cliffs; Giardia; Molecular similarity; SAS maps; Structure activity relationships; Trichomonas

Indexed keywords

BENZIMIDAZOLE DERIVATIVE;

ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG STRUCTURE; GIARDIA LAMBLIA; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TRICHOMONAS VAGINALIS;

ANTIPROTOZOAL AGENTS; BENZIMIDAZOLES; GIARDIA LAMBLIA; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TRICHOMONAS VAGINALIS;

GIARDIA; GIARDIA INTESTINALIS; PROTOZOA; TRICHOMONAS; TRICHOMONAS VAGINALIS;

EID: 77957991633     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.09.019     Document Type: Article

References (43)

1. World Health Organization. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates, Geneva, 2001.
2. P. Upcroft, and J.A. Upcroft Clin. Microbiol. Rev. 14 2001 150
3. D.S. Berkman, A.G. Lescano, R.H. Gilman, S. Lopez, and M.M. Black Lancet 359 2002 564
4. G. Navarrete-Vazquez, M.D. Rojano-Vilchis, L. Yepez-Mulia, V. Melendez, L. Gerena, A. Hernandez-Campos, R. Castillo, and F. Hernandez-Luis Eur. J. Med. Chem. 41 2006 135
5. G. Navarrete-Vázquez, L. Yépez, A. Hernández-Campos, A. Tapia, F. Hernández-Luis, R. Cedillo, J. González, A. Martínez-Fernández, M. Martínez-Grueiro, and R. Castillo Bioorg. Med. Chem. 11 2003 4615
6. M. Andrzejewska, L. Yépez-Mulia, R. Cedillo-Rivera, A. Tapia, L. Vilpo, J. Vilpo, and Z. Kazimierczuk Eur. J. Med. Chem. 37 2002 973
7. D. Valdez-Padilla, S. Rodríguez-Morales, A. Hernández- Campos, F. Hernández-Luis, L. Yépez-Mulia, A. Tapia-Contreras, and R. Castillo Bioorg. Med. Chem. 17 2009 1724
8. F. Ooms Curr. Med. Chem. 7 2000 141
9. J.L. Medina-Franco, F. Lopez-Vallejo, and R. Castillo Educ. Quím. 17 2006 452
10. H. Kubinyi Drug Discovery Today 2 1997 457
11. H. Kubinyi Drug Discovery Today 2 1997 538
12. T. Scior, J.L. Medina-Franco, Q.T. Do, K. Martinez-Mayorga, J.A. Yunes Rojas, and P. Bernard Curr. Med. Chem. 16 2009 4297
13. G. Klebe J. Mol. Med. 78 2000 269
14. L. Peltason, and J. Bajorath Chem. Biol. 14 2007 489
15. G.M. Maggiora J. Chem. Inf. Model. 46 2006 1535
16. R. Guha, and J.H. VanDrie J. Chem. Inf. Model. 48 2008 646
17. J. Bajorath, L. Peltason, M. Wawer, R. Guha, M.S. Lajiness, and J.H. Van Drie Drug Discovery Today 14 2009 698
18. G. Schneider, W. Neidhart, T. Giller, and G. Schmid Angew. Chem., Int. Ed. 38 1999 2894
19. H. Eckert, and J. Bajorath Drug Discovery Today 12 2007 225
20. J.L. Medina-Franco, K. Martinez-Mayorga, M.A. Giulianotti, R.A. Houghten, and C. Pinilla Curr. Comput.-Aided Drug Des. 4 2008 322
21. L. Peltason, and J. Bajorath J. Med. Chem. 50 2007 5571
22. R. Guha, and J.H. Van Drie J. Chem. Inf. Model. 48 2008 1716
23. Shanmugasundaram, V Maggiora, G. M. 222nd ACS National Meeting, Chicago, IL, United States; American Chemical Society, Washington, D. C: Chicago, IL, United States, 2001.
24. M. Wawer, L. Peltason, N. Weskamp, A. Teckentrup, and J. Bajorath J. Med. Chem. 51 2008 6075
25. L. Peltason, Y. Hu, and J. Bajorath ChemMedChem 4 2009 1864
26. J.L. Medina-Franco, K. Martínez-Mayorga, A. Bender, R.M. Marín, M.A. Giulianotti, C. Pinilla, and R.A. Houghten J. Chem. Inf. Model. 49 2009 477
27. L. Peltason, P. Iyer, and J. Bajorath J. Chem. Inf. Model. 50 2010 1021
28. G. Navarrete-Vázquez, R. Cedillo, A. Hernández-Campos, L. Yépez, F. Hernández-Luis, J. Valdez, R. Morales, R. Cortés, M. Hernández, and R. Castillo Bioorg. Med. Chem. Lett. 11 2001 187
29. J. Valdez, R. Cedillo, A. Hernandez-Campos, L. Yepez, F. Hernandez-Luis, G. Navarrete-Vazquez, A. Tapia, R. Cortes, M. Hernandez, and R. Castillo Bioorg. Med. Chem. Lett. 12 2002 2221
30. P. Jaccard Bull. Soc. Vaudoise Sci. Nat. 37 1901 547
31. P. Willett, J.M. Barnard, and G.M. Downs J. Chem. Inf. Comput. Sci. 38 1998 983
32. Molecular Operating Environment (MOE), version 2009.10, Chemical Computing Group, Montreal, Quebec, Canada. http://www.chemcomp.com (accesssed August, 2010).
33. Canvas, version 1.3, Schrödinger, LLC, New York, NY, 2010.
34. M. Sastry, J.F. Lowrie, S.L. Dixon, and W. Sherman J. Chem. Inf. Model. 50 2010 771
35. Conformational analysis for molecules with rotatable bonds was conducted by means of systematic search with torsions of 60° using MMFF94 force field. Equilibrium geometry calculations were carried out for the minimum energy conformer using PM3 semiempirical method.
36. Spartan, version 2002, Wavefunction, Irvine, CA. http://www.wavefun.com (accessed August, 2010).
37. A similar term, 'R-hopping' was proposed by Prof. Jürgen Bajorath (personal communication).
38. P. Willett Drug Discovery Today 11 2006 1046
39. D. Rogers, and M. Hahn J. Chem. Inf. Model. 50 2010 742
40. The only exception were regions II and III of the SAS map for T. vaginalis obtained with TGD; both regions have similar population.
41. M.A. Johnson, and G.M. Maggiora Concepts and Applications of Molecular Similarity 1990 Wiley New York
42. By analogy with the SAS maps, consensus SAS maps could be analyzed quantitatively dividing the maps into four quadrants by imposing thresholds for activity and molecular similarity.
43. Related methyl 1H-benzimidazole-2-yl-carbamate derivatives are strong selective inhibitors of tubulin polymerization. However, it is required that the benzimidazole scaffold has a 2-methylcarbamate group and hydrogen at position 1. The mechanism of non 2-methylcarbamates remains to be determined.